155 related articles for article (PubMed ID: 32035992)
1. The applicability and utility of immunohistochemical biomarkers in bladder pathology.
Akgul M; MacLennan GT; Cheng L
Hum Pathol; 2020 Apr; 98():32-55. PubMed ID: 32035992
[TBL] [Abstract][Full Text] [Related]
2. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 Antibody Comparison in Urothelial Carcinoma.
Rijnders M; van der Veldt AAM; Zuiverloon TCM; Grünberg K; Thunnissen E; de Wit R; van Leenders GJLH
Eur Urol; 2019 Mar; 75(3):538-540. PubMed ID: 30497882
[No Abstract] [Full Text] [Related]
4. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
[TBL] [Abstract][Full Text] [Related]
5. Significantly increased accuracy of urothelial carcinoma detection in destained urine slides with combined analysis of standard cytology and CK-20 immunostaing.
Soyuer I; Tokat F; Tasdemir A
Acta Cytol; 2009; 53(3):357-60. PubMed ID: 19534284
[No Abstract] [Full Text] [Related]
6. Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.
Babu S; Mockler DC; Roa-Peña L; Szygalowicz A; Kim NW; Jahanfard S; Gholami SS; Moffitt R; Fitzgerald JP; Escobar-Hoyos LF; Shroyer KR
Mod Pathol; 2019 May; 32(5):717-724. PubMed ID: 30443013
[TBL] [Abstract][Full Text] [Related]
7. Adult urinary bladder tumors with rhabdomyosarcomatous differentiation: clinical, pathological and immunohistochemical studies.
Bing Z; Zhang PJ
Diagn Pathol; 2011 Jul; 6():66. PubMed ID: 21762516
[TBL] [Abstract][Full Text] [Related]
8. Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report.
Montironi R; Santoni M; Goteri G; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M
Hum Pathol; 2015 Jul; 46(7):1040-4. PubMed ID: 25912755
[TBL] [Abstract][Full Text] [Related]
9. Expression of uroplakin II and GATA-3 in bladder cancer mimickers: caveats in the use of a limited panel to determine cell of origin in bladder lesions.
Leivo MZ; Tacha DE; Hansel DE
Hum Pathol; 2021 Jul; 113():28-33. PubMed ID: 33887302
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
[TBL] [Abstract][Full Text] [Related]
11. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
[TBL] [Abstract][Full Text] [Related]
12. PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall.
Legesse T; Matoso A; Epstein JI
Hum Pathol; 2019 Dec; 94():11-15. PubMed ID: 31669177
[TBL] [Abstract][Full Text] [Related]
13. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
14. [Nephrogenic bladder adenoma associated with glandular cystitis. Immunohistochemical study and significance].
Martínez Díaz F; Rico Galiano JL; Vicente Ortega V; Bernal Gilar M; Fontana Compiano LO; Ortuño Pacheco G
Actas Urol Esp; 2002 Jun; 26(6):416-9. PubMed ID: 12189737
[TBL] [Abstract][Full Text] [Related]
15. ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology.
Amin MB; McKenney JK; Paner GP; Hansel DE; Grignon DJ; Montironi R; Lin O; Jorda M; Jenkins LC; Soloway M; Epstein JI; Reuter VE;
Eur Urol; 2013 Jan; 63(1):16-35. PubMed ID: 23083804
[TBL] [Abstract][Full Text] [Related]
16. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival.
Luo JH; Xie D; Liu MZ; Chen W; Liu YD; Wu GQ; Kung HF; Zeng YX; Guan XY
Int J Cancer; 2008 Jun; 122(11):2554-61. PubMed ID: 18246597
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia.
Hodges KB; Lopez-Beltran A; Emerson RE; Montironi R; Cheng L
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):401-10. PubMed ID: 20505509
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma.
Zizzi A; Montironi MA; Mazzucchelli R; Scarpelli M; Lopez-Beltran A; Cheng L; Paone N; Castellini P; Montironi R
Diagn Pathol; 2013 Jul; 8():111. PubMed ID: 23819605
[TBL] [Abstract][Full Text] [Related]
19. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
Poyet C; Buser L; Roudnicky F; Detmar M; Hermanns T; Mannhard D; Höhn A; Rüschoff J; Zhong Q; Sulser T; Moch H; Wild PJ
J Clin Pathol; 2015 Oct; 68(10):819-24. PubMed ID: 26251520
[TBL] [Abstract][Full Text] [Related]
20. Beclin 1 and bcl-2 expressions in bladder urothelial tumors and their association with clinicopathological parameters.
Baspinar S; Bircan S; Yavuz G; Kapucuoglu N
Pathol Res Pract; 2013 Jul; 209(7):418-23. PubMed ID: 23722017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
